[Therapy related leukemia with 11q23 abnormality induced by chemotherapy consisted of docetaxel for advanced prostatic carcinoma: case report].

Abstract

A balanced translocation involving 11q23 (MLL gene) could be observed in therapy related leukemia (TRL) patients generally treated with topoisomerase II inhibitors. Few reports have been published on TRL following docetaxel administration. Herein, we report a patient who developed acute myelomonocytic leukemia (AMMoL) with t (9; 11) (p22; q23) following chemotherapy mainly consisted of docetaxel for advanced prostatic carcinoma. A 69-year-old man was treated with a systemic chemotherapy containing docetaxel (total dose = 585 mg) for hormone-refractory metastatic poorly differentiated prostate carcinoma. Although, no disease progression of the prostatic carcinoma was observed, AMMoL with t (9; 11) (p22; q23) developed only ten months later from the administration of docetaxel. Docetaxel was considered to be the cause of TRL because of the presence of t (9; 11) (p22; q23) translocation and clinical course.

• Authors: Kazuyuki Numakura, Norihiko Tsuchiya, Tomonori Habuchi, Naoto Takahashi
• Journal: Nihon Hinyokika Gakkai zasshi. The japanese journal of urology (Nihon Hinyokika Gakkai Zasshi) Vol. 100 Issue 5 Pg. 580-5 (Jul 2009) ISSN: 0021-5287 [Print] Japan
• PMID: 19663246 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Taxoids
• Docetaxel

Topics

• Aged
• Antineoplastic Agents (administration & dosage, adverse effects)
• Carcinoma (pathology, therapy)
• Chromosomes, Human, Pair 11 (genetics)
• Combined Modality Therapy
• Docetaxel
• Humans
• Leukemia, Myelomonocytic, Acute (chemically induced, genetics)
• Liver Neoplasms (drug therapy, secondary)
• Male
• Neoplasm Recurrence, Local (drug therapy)
• Neoplasms, Second Primary
• Prostatectomy
• Prostatic Neoplasms (pathology, therapy)
• Taxoids (administration & dosage, adverse effects)
• Translocation, Genetic